172 related articles for article (PubMed ID: 37661910)
1. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
3. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Perisano C; Vitiello R; Sgambato A; Greco T; Cianni L; Ragonesi G; Malara T; Maccauro G; Martini M
J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 3):289-294. Congress of the Italian Orthopaedic Research Society. PubMed ID: 33261292
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
9. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S; Ueki A; Lasota J; Komura M; Sheema AN; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Miettinen M; Takahashi S
J Pathol Clin Res; 2023 May; 9(3):195-207. PubMed ID: 36754859
[TBL] [Abstract][Full Text] [Related]
10. Immune microenvironment of intimal sarcomas: Adaptive immune resistance with potential therapeutic implications.
Birkness-Gartman JE; Thomas DL; Engle LL; Voltaggio L; Thompson ED
Am J Clin Pathol; 2024 Mar; 161(3):256-263. PubMed ID: 37921094
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
14. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
15. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
16. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
17. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P
Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817
[TBL] [Abstract][Full Text] [Related]
18. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]